MULTIPLE MYELOMA

In the MagnetisMM-1 study, elranatamab induces response with tolerable safety in patients with relapsed or refractory multiple myeloma.

Two year after being diagnosed with stage II multiple myeloma, a 78-year-old female patient was still receiving daratumumab plus lenalidomide maintenance and presented with mild fatigue during a routine follow-up.

Rapid responses and tolerable safety was shown with minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

CARTITUDE-1 update shows continued deep and durable response with iltacabtagene autoleucel in patients with heavily pretreated multiple myeloma.

Thomas G. Martin, MD, discusses the use of anti-CD38 antibodies in patients with multiple myeloma.

During a recent tweet chat with Alexander M. Lesokhin, MD, a hematologic oncologist with Memorial Sloan Kettering Cancer Center, joined Targeted Oncology to discuss the case of a 72-year-old White man with newly-diagnosed multiple myeloma.

At a live virtual event, David H. Vesole, MD, PhD, explained to other clinicians the use of daratumumab in the treatment of patients with newly diagnosed multiple myeloma who are either eligible or ineligible for autologous stem cell transplant.

During a Targeted Oncology Case-Based Roundtable event, Noa Biran, MD, discussed the case of a 51-year-old man with newly-diagnosed multiple myeloma.

The FDA has granted a fast track designation to ALLO-605, a next-generation allogeneic CAR T-cell therapy for the treatment of relapsed or refractory multiple myeloma.

During a Targeted Oncology Case-Based Roundtable event, Natalie S. Callander, MD, discussed the case of a 78-year-old patients with multiple myeloma.

Joseph Mikhael, MD, discussed the case of a 51-year-old patients with multiple myeloma.

Two years after being diagnosed with multiple myeloma and treated with the Dara-Rd regimen as induction therapy, a 78-year-old patient presented with mild fatigue during routine follow-up. James E. Hoffman, MD, discussed the case with a group of peers.

In a rountable Targeted Oncology talk, Sikander Ailawadhi, MD, leads a discussion on whether MRD affects multiple myeloma treatment decisions. He is joined by Ricardo Parrondo, MD Jeffrey Bubis, DO, Mathew Luke, MD, Sushma Simha Nakka, MD, and Thomas Cartwright, MD.

A warning from the FDA highlights that an increased rate of death has been observed in patients with multiple myeloma who are undergoing treatment with the FDA-approved agent melphalan flufenamide in combination with dexamethasone in the phase 2 OCEAN clinical trial.

During a Targeted Oncology Case-Based Roundtable event, Clifton C. Mo, MD, discussed the treatment of newly-diagnoses multiple myeloma.

Two years after being diagnosed with stage II multiple myeloma, a patient continuing on daratumumab plus lenalidomide maintenance showed concerning symptoms during routine follow-up, explained Ruben Niesvizky, MD.

The treatment plan for a woman with multiple myeloma, including which imaging to order, choice of second-line therapy, managing comorbidities, and backbone therapy choice, was discussed during a recent Cased-Base Roundtable event led by Clifton C. Mo, MD.

In an interview with Targeted Oncology, Omar Nadeem, MD, the clinical director of the Myeloma Cellular Therapies Program at the Harvard Medical School and physician at the Dana-Farber Cancer Institute, discusses transplant and quadruplet regimens in newly diagnosed multiple myeloma.

Immune-checkpoint inhibitor therapy, involving anti–CTLA-4 and anti–PD-1/ PD-L1 agents, has transformed the treatment of melanoma. Nonetheless, even with combination anti–PD-1 and anti–CTLA-4 therapy, nearly 50% of patients die of their disease at 5 years.

Larry D. Anderson, Jr, MD, PhD, discusses the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

David H. Vesole, MD, PhD, discussed the case of a 82-year old patient with transplant-ineligible multiple myeloma.

The FDA has granted approval to the combination of daratumumab and hyaluronidase-fihj and pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.

The FDA has placed a partial clinical hold on clinical trials evaluating the first-in-class peptide-drug conjugate, melphalan flufenamide pending a full benefit/risk profile on the agent for use as an early line of therapy in patients with relapsed or refractory multiple myeloma.

During a Targeted Oncology Case-Based Roundtable event, Olalekan O. Oluwole, MD, MBBS, MPH, leads a discussion around identifying prognostic factors for a patients with transplant-eligible multiple myeloma.

Joseph Mikhael, MD, debated with a group pf peers about the impact of using frontline daratumumab on subsequent therapy.

Mounzer Agha, MD, discusses the phase 2 CARTITUDE-2 trial looking at ciltacabtagene autoleucel in patients with multiple myeloma.

Regarding the case of a 51-year-old man who first presented with pallor and worsening fatigue on exertion and was diagnosed with transplant-eligible multiple myeloma, Rafael Fonseca, MD, discussed available treatment options.

Intensifying daratumumab induction therapy may improve responses to therapy in patients with ultra­ high-risk multiple myeloma or primary plasma cell leukemia, according to prospective study results.

Benefit was seen with daratumumab maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone.

Intensified induction therapy with daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone followed by bortezomib-augmented autologous stem cell transplant resulting in deep remissions or patients with ultra¬ high-risk multiple myeloma or primary plasma cell leukemia.